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We and others have recently cloned a non-receptor,
calcium-dependent tyrosine kinase (CADTK; also known
as PYK2, CAKb, and RAFTK) that shares both overall
domain structure and 45% amino acid identity with
p125FAK. We have studied the signaling, activation, and
potential function of these related enzymes in GN4 rat
liver epithelial cells that express CADTK and p125FAK at
roughly similar levels. p125FAK is nearly fully tyrosine-
phosphorylated in resting GN4 cells. In contrast, while
CADTK is not tyrosine-autophosphorylated in un-
treated cells, angiotensin II increases CADTK Tyr(P) by
5–10-fold. With regard to signaling, CADTK activation is
correlated with stimulation of c-Jun N-terminal kinase
and p70S6K pathways but not with the stimulation of
mitogen-activated protein kinase or p90RSK. In this re-
port we assessed the contribution of CADTK and
p125FAK to tyrosine phosphorylation of focal contact
proteins. In adherent GN4 cells, the constitutive activity
of p125FAK was correlated with basal paxillin, tensin,
and p130CAS tyrosine phosphorylation. A rapid increase
in the tyrosine phosphorylation of each protein was de-
tected after treatment with angiotensin II or other ago-
nists that stimulate CADTK; the prolonged 3–4-fold in-
crease in paxillin tyrosine phosphorylation was the
most substantial change. In the WB cell line that ex-
presses 3-fold less CADTK than GN4 cell line agonist-de-
pendent paxillin tyrosine phosphorylation is similarly
reduced. Immunoprecipitation of CADTK from GN4
cells revealed CADTKzpaxillin complexes that persisted
in 500 mM NaCl but not in 0.1% SDS cell lysis buffer. The
complexes were largely independent of the tyrosine
phosphorylation state of either protein. Surprisingly,
we did not detect p125FAKzpaxillin complexes in immu-
noprecipitates using either of two p125FAK antibodies.
When CADTK and p125FAK were transiently overex-
pressed in 293(T) cells, both enzymes associated with
paxillin, but the avidity of CADTK appeared to be
greater. In addition, in transfected 293(T) cells, com-
plexes between CADTK and another potential substrate,
p130CAS, were detected. In summary, in GN4 rat liver
epithelial cells stimulation of CADTK was highly corre-
lated with paxillin tyrosine phosphorylation; in addi-
tion, CADTK but not p125FAK was complexed to paxillin
at detectable levels. This suggests that agonist-depend-
ent cytoskeletal changes in epithelial cells might pro-
ceed, in part, by CADTK-dependent mechanisms.
The once separate fields of cell structure and signal trans-
duction have converged due to a number of recent observations.
Growth factors and hormones are now known to regulate cell
shape and mobility; conversely, proteins involved in cell attach-
ment and cytoskeleton formation can clearly be induced to
generate intracellular signals (1–6). For example, integrins
engagement stimulates tyrosine phosphorylation (7–10) and
alters gene expression (6, 11).
Several years ago our laboratory noted that EGF1 treatment
of rat liver epithelial cells produced several waves of protein
tyrosine phosphorylation, the second occurring ;30 s after the
initial accumulation of EGF-dependent Tyr(P) substrates (12).
At least some of the secondary substrates, those in the p115–
130-kDa region, corresponded in molecular size to Tyr(P) sub-
strates observed following integrin cross-linking. The delayed
EGF-dependent activity was, in part, due to stimulation of a
soluble protein tyrosine kinase that appeared to be activated by
the small EGF-dependent calcium signal (13). Kinase activa-
tion was even greater with the higher intracellular calcium
levels produced by angiotensin II (Ang II), [Arg8]vasopressin,
or epinephrine (13, 14). Thapsigargin which increases intracel-
lular calcium without stimulating protein kinase C also stim-
ulated tyrosine phosphorylation, an effect greatly diminished
by pretreatment of cells with BAPTA-AM, an intracellular
calcium chelator (13, 14).
We have now purified the calcium-dependent tyrosine kinase
(CADTK) from rat liver epithelial cells (15) and obtained a
complete cDNA (16). Rat CADTK encodes the same protein as
human PYK2 (17), RAFTK (18), and rat CAKb (19). CADTK
and p125FAK are highly related, and thus comparison is in-
structive. The 45% overall amino acid identity is particularly
striking within the tyrosine kinase and C-terminal domains.
p125FAK, originally identified as a v-src substrate is localized to
focal adhesions (20) where a network of proteins connects the
extracellular matrix to the actin cytoskeleton (4) and is acti-
vated in response to cellular interaction with the extracellular
matrix (7, 10, 21, 22). This latter effect is often correlated with
but may or may not be causally related to signals that activate
the MAPK pathway (23–27). In summary, p125FAK sits at a
conceptual and physical juncture where it is capable of inte-
grating cell structure and signaling.
p125FAK does not contain SH2 or SH3 domains but can
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interact with proteins containing SH2 and SH3 binding do-
mains. When autophosphorylated on tyrosines, p125FAK cre-
ates binding sites for other SH2 domain-containing proteins
including Src tyrosine kinase family members (28–30).
p125FAK also exhibits a proline-rich region that can interact
with SH3 domain-containing proteins including p130CAS (31–
34). Additionally, the C terminus encompasses the focal adhe-
sion targeting domain that forms direct or indirect complexes
with several focal adhesion proteins including paxillin (35). The
association with paxillin presumably occurs through two vin-
culin homology domains within the C-terminal focal adhesion
targeting sequence; in turn, paxillin binding has been sug-
gested to localize p125FAK to focal adhesions (36). However,
others have reported that paxillin association may not be re-
quired for p125FAK focal adhesions’ localization (37). As noted,
tyrosine-phosphorylated p125FAK binds (and may activate) Src
family tyrosine kinases, concentrating these enzymes and
other proteins within focal adhesions, in effect assembling a
large potential signaling complex (5, 6, 24).
p125FAK has been most extensively studied in fibroblasts, a
cell type that does not express CADTK (19) (data not shown).
The latter kinase is abundant in neural tissue and is expressed
in epithelial cells and hematopoietic cells (16–18). However,
CADTK is not excluded from cells of mesenchymal origin as we
have found it to be activated by multiple agonists in rat smooth
muscle cells.2 While some cells express only one or the other
enzyme, at least several cell types including rat liver epithelial
cells express CADTK and p125FAK. CADTK is rapidly activated
by a Gq protein-coupled signal using either the calcium- or
protein kinase C-dependent branches of phospholipase C-acti-
vated pathways (15–17). Neither the effect of calcium nor pro-
tein kinase C appear to be direct (calcium does not directly
activate the purified enzyme and protein kinase C activation is
slower). In Swiss 3T3 cells, p125FAK is rapidly stimulated by
bombesin and other neuropeptides (38–41). However, in cells
in which both enzymes are expressed the stimulation of
CADTK activity is more rapid, of greater magnitude, and is far
more dependent upon hormonal and growth factor stimulation
than changes in p125FAK (16, 17).2 For example, in adherent
WB and GN4 cells, p125FAK exhibits a high basal level of
tyrosine phosphorylation and is only minimally increased by
Ang II treatment, whereas CADTK is stimulated by 5–10-fold
(16). In many instances p125FAK activation is correlated with
stimulation of the MAPK pathway although a direct causal
relationship is not universally agreed upon. The calcium-de-
pendent activation of CADTK in GN4 liver epithelial cells does
not activate MAPK (16) but is correlated with substantial in-
creases in c-Jun N-terminal kinase and the p70S6 kinase
(p70S6K) activities (16, 42, 43).
But what of CADTK’s interaction with and phosphorylation
of cytoskeletal proteins, a dominant feature of p125FAK biology?
In this article we report that Ang II treatment stimulates the
tyrosine phosphorylation of paxillin, tensin, and p130CAS. The
effect on paxillin phosphorylation is the most dramatic and
prolonged. While p125FAK probably regulates basal paxillin
tyrosine phosphorylation in adherent GN4 cells (since CADTK
activity is minimal), the rapid and extensive paxillin tyrosine
phosphorylation observed after agonist stimulation correlates
with both the activation and expression of CADTK. Moreover,
even though the levels of tyrosine-phosphorylated p125FAK and
CADTK are similar in GN4 cells, paxillin forms a noncovalent
complex with CADTK, whereas paxillinzp125FAK complexes
could not be detected. Overexpression of CADTK and p125FAK
by transient transfection again revealed the increased affinity
of paxillin for CADTK and also demonstrated CADTKzp130CAS
complexes. Thus, in GN4 cells, hormonal activation of CADTK
significantly increases paxillin tyrosine phosphorylation, acute
changes that are played out upon a background level of extra-
cellular matrix dictated protein tyrosine phosphorylation me-
diated, in part, by p125FAK.
EXPERIMENTAL PROCEDURES
Materials—Ang II was purchased from Sigma and prepared in 50 mM
acetic acid prior to use. Thapsigargin and BAPTA-AM were purchased
from Sigma and Biomol, respectively, and prepared in Me2SO. Anti-
paxillin monoclonal antibody and anti-Tyr(P) monoclonal antibody
(RC20H) were purchased from Transduction Laboratories. Anti-Tyr(P)
monoclonal antibody (PT66) was purchased from Sigma. Anti-p125FAK,
monoclonal antibody 2A7, and polyclonal antibody BC3 were gener-
ously provided by Drs. Tom Parsons (University of Virginia) and Mi-
chael Schaller (University of North Carolina). Anti-p125FAK polyclonal
antibody, A17, was purchased from Santa Cruz Biotechnology. Anti-
p130CAS monoclonal and polyclonal antibodies were purchased from
Transduction Laboratories and Santa Cruz Biotechnology, respectively.
Anti-tensin monoclonal antibody was generously provided by Dr. Keith
Burridge (University of North Carolina). Rabbit anti-rat CADTK poly-
clonal antisera were raised to two glutathione S-transferase fusion
proteins (amino acids 1–80 and 680–860 of rat CADTK, respectively) as
described previously (16).
Cell Cultures—Rat liver epithelial cells (GN4 or WB) were cultured
in Richter’s minimal essential medium supplemented with 10% fetal
bovine serum and 0.1 mM insulin as described earlier (15). Human 293
embryonic kidney cells with SV40 T antigen (human 293(T) cells) were
kindly provided by Dr. Brian Varnum (Amgen) and grown in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum.
Cell Lysate Preparation—Cell lysis was performed essentially as
described previously (15). Briefly, cells treated with agonists were
scraped into ice-cold cell lysis buffer. One of three lysis buffers was used
and referred to as follows: (i) low salt lysis buffer (150 mM NaCl, 20 mM
Tris (pH 7.5), 1% Triton X-100, 5 mM EDTA, 50 mM NaF, and 10% (v/v)
glycerol); (ii) high salt buffer (500 mM NaCl, 20 mM HEPES (pH 7.3), 1%
Triton X-100, 5 mM EDTA, 50 mM NaF, and 10% (v/v) glycerol); or (iii)
RIPA lysis buffer (150 mM NaCl, 20 mM Tris (pH 7.5), 1% Triton X-100,
2 mM EDTA, 10% (v/v) glycerol, 0.1% SDS, and 0.5% deoxycholate). To
all cell lysis buffers the following reagents were added before use: 1 mM
Na3VO4, 20 mg/ml phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin,
and 100 kallikrein inhibitor units of aprotinin per ml. Cell lysates were
clarified by centrifugation at 14,000 3 g for 10 min at 4 °C and the
protein content determined prior to immunoprecipitation.
Anti-Tyr(P), p125FAK, CADTK, and Paxillin Immunoprecipitation
and Immunoblotting—In a typical experiment, 500 mg of cell lysate was
immunoprecipitated by incubation with the antibody for 2 h at 4 °C,
followed by addition of 20 ml of protein A or protein A/G-agarose beads
(Santa Cruz) for 1 h. Immune complexes were collected by centrifuga-
tion (in some cases the supernatant was used for a second antibody
immunoprecipitation). Immune complexes were then washed three
times with the lysis buffer and then resuspended in SDS-PAGE sample
buffer. Samples were subjected to SDS-PAGE, transferred to Immo-
bilon (Millipore), and detected by incubating the blots with the specified
antibody as described (15). Immunoblots were incubated with either
goat anti-rabbit or anti-mouse horseradish peroxidase-conjugated anti-
bodies and developed using enhanced chemiluminescence according to
the manufacturer’s procedure (Amersham Corp.). When indicated, im-
munoblots were stripped in the buffer (62.5 mM Tris (pH 6.8), 2% SDS,
100 mM b-mercaptoethanol) at 50 °C for 30 min, and reprobed with
another specific antibody.
Transient Expression of CADTK and p125FAK in Human 293(T)
Cells—The full-length CADTK cDNA was isolated as described (16) and
was subcloned into a pcDNA3 vector (Invitrogen). Human p125FAK
cDNA, subcloned into the pcDNA3 vector, was kindly provided by Dr.
William Cance (University of North Carolina). The control vector
(pcDNA3), pcDNA3-CADTK, and pcDNA3-p125FAK were transfected
into subconfluent human 293(T) cells with LipofectAMINE according to
the manufacturer’s procedure (Life Technologies, Inc.). After 48 h,
transfected cells were harvested and lysed on ice with low salt buffer,
and the lysates were analyzed by immunoprecipitation, followed by
immunoblotting with anti-Tyr(P), CADTK, p125FAK, paxillin, or
p130CAS.
2 A. Brinson, X. Li, Y. He, H. S. Earp, and L. M. Graves, unpublished
results.
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RESULTS
Ang II Increases Paxillin, Tensin, and p130CAS Tyrosine
Phosphorylation—As previously reported, Ang II and thapsi-
gargin increase the tyrosine phosphorylation of proteins with a
molecular weight of p115–130, p72/75, and p66 (13–15). One of
the 115-kDa tyrosine-phosphorylated proteins was identified
as the major calcium-dependent tyrosine kinase (CADTK).
Since integrin engagement stimulates p125FAK and paxillin
Tyr(P) and Ang II has been shown to increase paxillin tyrosine
phosphorylation in smooth muscle cells (44, 45), we tested
whether one of the GN4 cell p72/75-kDa tyrosine phosphopro-
teins was paxillin. Immunoprecipitation and anti-Tyr(P) im-
munoblot revealed that Ang II treatment of GN4 cells in-
creased paxillin tyrosine phosphorylation by 90 s, an effect that
persisted for at least 30 min (Fig. 1A). Paxillin tyrosine phos-
phorylation could be detected at 15–30 s coincident with the
tyrosine phosphorylation of CADTK (data not shown). Ang II
stimulation also altered paxillin electrophoretic mobility, sug-
gesting sequential, multi-site phosphorylation on Tyr, Ser, or
Thr residues. The mobility shift, while detected at early time
points, became more pronounced at 5 min.
Ang II treatment also rapidly increased tensin (Fig. 1C) and
p130CAS (Fig. 1E) tyrosine phosphorylation. In contrast to pax-
illin, both tensin and p130CAS reached their maximum level of
tyrosine phosphorylation by 90 s and gradually decreased their
Tyr(P) content. This more closely parallels the time course of
CADTK tyrosine phosphorylation (Fig. 1G) but may also sug-
gest that tensin and p130CAS are more susceptible to tyrosine
phosphatases than paxillin. Tensin but not p130CAS also exhib-
ited a significant gel mobility shift with Ang II treatment (Fig.
1C). The gel mobility shift persists even though total Tyr(P) as
assessed by immunoblot recedes. It is likely that the gel mobil-
ity shift of both paxillin and tensin progress as due to Ser/Thr
phosphorylations or by tyrosine phosphorylation at new sites.
Tryptic phosphopeptide mapping followed by phosphoamino
analysis may resolve this issue.
Agonist-dependent CADTK and Paxillin Tyrosine Phospho-
rylation Are Correlated—Rat liver epithelial cells express both
p125FAK and CADTK. Stimulation with Ang II leads to a vari-
able alteration in p125FAK tyrosine phosphorylation and au-
tokinase activity ranging from barely detectable to 50–100%
increases (15). This is presumably due to the fact that p125FAK
is near maximally phosphorylated in adherent, confluent GN4
cells. In contrast, CADTK tyrosine phosphorylation is barely
detectable in control cells but is rapidly induced (5–10-fold) by
Ang II or other agonists. To test whether CADTK or p125FAK
stimulation correlated with acute changes in paxillin tyrosine
phosphorylation, GN4 cells were treated with a series of ago-
nists known to stimulate CADTK followed by comparison of the
Tyr(P) content of paxillin, CADTK, and p125FAK. Agonists that
significantly increased CADTK tyrosine phosphorylation (Fig.
2A) were the most effective at acutely increasing paxillin tyro-
sine phosphorylation (Fig. 2C). In general, the extent of
CADTK and paxillin Tyr(P) was correlated. For example, pro-
longed EGF treatment (5 min) slightly increased CADTK tyro-
sine phosphorylation (Fig. 2A, lane 3) and slightly stimulated
paxillin tyrosine phosphorylation (Fig. 2C, lane 3), whereas
Ang II and sorbitol maximally stimulated CADTK and paxillin
Tyr(P) content. In contrast, p125FAK tyrosine phosphorylation
was only minimally altered by agonist treatment (Fig. 2B).
FIG. 1. Ang II stimulates paxillin, p130CAS, tensin, and CADTK
tyrosine phosphorylation in GN4 cells. Rat liver epithelial cells
(GN4) were treated with Ang II (1 mM) for the times indicated. Cells
were then lysed, and immunoprecipitates (IP) were prepared using
anti-paxillin, tensin, p130CAS, and CADTK antibodies. Immunoprecipi-
tates were analyzed by SDS-PAGE, followed by transfer of proteins to
Immobilon and immunoblotting with the anti-Tyr(P) antibody
(RC20H). Blots were stripped and reprobed with anti-paxillin (B), and
anti-tensin (D), anti-p130CAS (F), and anti-CADTK (H) antibodies,
respectively.
FIG. 2. CADTK agonists increase paxillin tyrosine phosphoryl-
ation in GN4 cells. GN4 cells were treated with EGF (100 ng/ml), Ang
II (1 mM), thapsigargin (Thaps) (2 mM), NaCl (0.7 M), sorbitol (0.4 M), and
phorbol esters (TPA) (100 nM) for the times indicated. Equal amounts of
cell lysate were immunoprecipitated (IP) with anti-Tyr(P) antibody
(pT66). The immunoprecipitates were then analyzed by SDS-PAGE,
followed by immunoblotting (IB) with anti-CADTK (A), anti-p125FAK
(B), and anti-paxillin (C) antibodies, respectively.
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Therefore, basal paxillin tyrosine phosphorylation may be de-
termined by constitutive p125FAK activity. The correlation be-
tween CADTK and paxillin tyrosine phosphorylation suggests
that Gq protein-coupled receptor and other agonists stimulate
additional paxillin tyrosine phosphorylation via CADTK.
Agonist-stimulated Paxillin Tyrosine Phosphorylation Corre-
lates with CADTK Expression and Extent of Activation—To
further examine the role of the two enzymes, Ang II-dependent
paxillin tyrosine phosphorylation was investigated in cells
known to express similar levels of p125FAK but different levels
of CADTK. We had previously shown that confluent GN4 cells
(derived by chemical transformation of a normal rat liver epi-
thelial cell line, WB) have ;3–4 times more Ang II-dependent
tyrosine phosphorylation than its parent WB cell (13). Immu-
noprecipitation with specific CADTK antiserum demonstrated
that GN4 cells exhibit ;4–5-fold higher maximal Ang II-de-
pendent CADTK tyrosine phosphorylation (90 s) than similarly
treated WB cells (16). Likewise, Ang II treatment resulted in
significantly more paxillin tyrosine phosphorylation in GN4
cells than in WB cells (Fig. 3A). p125FAK expression and tyro-
sine autophosphorylation in response to Ang II stimulation was
similar in the GN4 and WB cell lines (Fig. 3C). Thus the similar
basal level of paxillin tyrosine phosphorylation in WB and GN4
(Fig. 3A) cells correlated with the equivalent p125FAK levels
(Fig. 3C). The much greater Ang II-dependent paxillin tyrosine
phosphorylation in GN4 cells was observed consistently. It
supports the hypothesis that increased CADTK activation
acutely regulates paxillin Tyr(P) content.
Intracellular Calcium Chelation and Cytochalasin D Block
Ang II-dependent Paxillin Tyrosine Phosphorylation—CADTK
activation by Ang II or thapsigargin is, in part, a calcium-de-
pendent process. To test the calcium dependence of Ang II and
thapsigargin-stimulated paxillin tyrosine phosphorylation,
GN4 cells were preincubated with the cell-permeable, calcium
chelator BAPTA-AM that abolishes the calcium signal in these
cells (13, 14). BAPTA attenuated the acute increase in both
CADTK and paxillin tyrosine phosphorylation in response to
Ang II (Fig. 4, A and C). The effect of BAPTA was not complete
since Ang II also regulates CADTK activity via protein kinase
C. However, BAPTA, which completely blocked thapsigargin-
dependent CADTK activation (Fig. 4A, lane 6), almost totally
inhibited thapsigargin-dependent paxillin tyrosine phosphoryl-
ation (Fig. 4C, lane 6). Preincubation with BAPTA-AM alone
decreased both basal p125FAK and paxillin tyrosine phospho-
rylation (Fig. 4B). These results suggest that calcium-depend-
ent activation of CADTK is in part responsible for initiating
paxillin tyrosine phosphorylation in response to Ang II and
thapsigargin.
Paxillin, a member of the complex of cytoskeletal proteins, is
concentrated at focal contacts, the cytoplasmic face of regions
attaching the cell to the extracellular matrix (46, 47). Cytocha-
lasin D, an agent that disrupts actin microfilaments and cy-
toskeletal movement, inhibits p125FAK tyrosine autophospho-
rylation and prevents paxillin tyrosine phosphorylation in
Swiss 3T3 cells (22, 39, 41, 48). To test whether cytochalasin D
inhibited CADTK, p125FAK, or paxillin tyrosine phosphoryla-
tion, GN4 cells were preincubated with cytochalasin D and
subsequently treated with Ang II or NaCl, another agonist that
stimulates CADTK activity (see Ref. 16 and Fig. 2). Cytocha-
lasin D pretreatment dramatically changed cell morphology
(data not shown) and partially inhibited Ang II and NaCl-
stimulated CADTK (Fig. 5, A and C) and basal p125FAK tyro-
sine phosphorylation (Fig. 5B). The effect of cytochalasin D on
paxillin tyrosine phosphorylation was even more dramatic;
both basal and stimulated paxillin Tyr(P) were nearly elimi-
nated by cytochalasin D pretreatment. If our thesis is correct,
FIG. 3. Comparison of paxillin tyrosine phosphorylation in
GN4 and WB cell lines in response to Ang II stimulation. Rat liver
epithelial cells (GN4 and WB cells) were treated with Ang II (1 mM,
90 s). Cells were then lysed, and immunoprecipitates (IP) were pre-
pared with anti-paxillin antibody (A and B) or anti-p125FAK antibody (C
and D). Immunoprecipitates were analyzed by SDS-PAGE, followed by
immunoblotting with anti-Tyr(P) antibody (RC20H) (A and C). Blot was
stripped and reprobed with anti-paxillin antibody (B) or anti-p125FAK
antibody (D).
FIG. 4. The intracellular calcium chelator, BAPTA-AM, inhib-
its CADTK tyrosine autophosphorylation and paxillin tyrosine
phosphorylation to a greater degree than it inhibits p125FAK
tyrosine phosphorylation. GN4 cells were pretreated with 50 mM
BAPTA-AM for 20 min, followed by Ang II (1 mM) and thapsigargin
(Thaps) (2 mM) stimulation (90 s). Cells were then lysed, and equal
amounts of cell lysates were immunoprecipitated (IP) with anti-CADTK
(A), anti-p125FAK (B), and anti-paxillin (C) antibodies. Immunoprecipi-
tates were analyzed by SDS-PAGE, followed by immunoblotting (IB)
with anti-Tyr(P) antibody (RC20H), respectively.
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i.e. that p125FAK is responsible for basal paxillin tyrosine phos-
phorylation in adherent cells and CADTK is responsible for the
hormonally induced increment, this experiment suggests that
both processes require an intact cytoskeleton.
Tyrosine-phosphorylated Paxillin Associates with CADTK in
Ang II-treated Cells—The results in Figs. 1–3 suggested that
Ang II stimulates paxillin tyrosine phosphorylation and that
this agonist-dependent process is best correlated with activa-
tion and expression of CADTK rather than p125FAK. Since
paxillin associates with p125FAK in chicken embryo fibroblasts
(37), we tested whether tyrosine-phosphorylated paxillin bound
to CADTK or p125FAK in control and Ang II-treated GN4 cells.
Confluent GN4 cells were treated with vehicle or Ang II for
90 s, lysed, and immunoprecipitated with antiserum to CADTK
or with one of two antibodies to p125FAK, 2A7 or A17. CADTK
tyrosine phosphorylation was stimulated in Ang II-treated
cells, and p125FAK, which runs slightly above the 115-kDa
CADTK, was tyrosine-phosphorylated in both control and Ang
II-stimulated GN4 cells (Fig. 6). Equal amounts of cell lysates
were used for all immunoprecipitations and were immuno-
blotted with the same anti-Tyr(P) antibody; thus, the result
depicted in Fig. 6 suggests that maximal level of tyrosine-
phosphorylated p125FAK is at least equivalent and in fact is
probably slightly greater than that of CADTK. Because we do
not have an antibody that recognizes both enzymes, we have
compared total Tyr(P) in the immunoprecipitated kinases. The
sequence and autophosphorylation sites in both kinases are
highly conserved. Moreover, we have mutated the predicted
major tyrosine autophosphorylation site of CADTK Tyr402 and
demonstrated that this mutation drastically decreases CADTK
autophosphorylation in the same manner that Tyr397 mutation
reduces p125FAK autophosphorylation.3 Thus, the equivalent
level of maximal tyrosine phosphorylation in GN4 cell CADTK
and p125FAK provides a reasonable indication that p125FAK
and CADTK expression are similar in these cells.
Surprisingly, 68–75-kDa range Tyr(P) proteins were associ-
ated with CADTK, but there was little or no 68–75-kDa Tyr(P)
protein associated with p125FAK (Fig. 6). Analysis of the
CADTK immunoprecipitation with paxillin antibody showed
that at least some of the 68–75-kDa Tyr(P) protein was paxillin
(see below). The result suggests that while paxillin can associ-
ate with p125FAK (see Refs. 36 and 37 and Fig. 9) in adherent
cells, little or no tyrosine-phosphorylated paxillin can be found
in precipitable p125FAKzpaxillin complexes.
Paxillin and CADTK Associate in Intact Cells—Having ob-
served CADTK association with tyrosine-phosphorylated pax-
illin in GN4 cells, we further investigated the nature of the
CADTKzpaxillin complex. GN4 cells were treated with vehicle,
Ang II, or thapsigargin and lysed in three different lysis buff-
ers, low salt, high salt, and 0.1% SDS RIPA buffer. Cell lysates
were first immunoprecipitated using anti-CADTK antiserum;
subsequently the CADTK-cleared lysate was reimmunoprecipi-
tated with anti-paxillin antibody. Following SDS-PAGE and
transfer, a paxillin immunoblot demonstrated nearly equal
amounts of paxillin present in CADTK immunocomplexes pre-
cipitated in low salt buffer from either control or agonist-
treated cells. Thus, Ang II or thapsigargin treatment did not
alter CADTK-paxillin association; the complex exists prior to
agonist treatment (Fig. 7A). The results were the same after
lysis in a high salt buffer (Fig. 7B), a condition that would
disrupt protein-protein association based on Tyr(P)-SH2 do-
main interaction. CADTK-paxillin association was eliminated
in 0.1% SDS suggesting that native conformation of one or both
proteins was required (Fig. 7C). The above results suggested
that CADTK-paxillin association in vivo is an intrinsic prop-
erty of the proteins and does not require CADTK or paxillin
tyrosine phosphorylation.
CADTK Appears to Bind More Avidly to Paxillin Than
p125FAK—We next tested whether disrupting the cytoskeleton
structure with cytochalasin D could disrupt the CADTK-paxil-
lin or p125FAK association. As shown in Fig. 8A, CADTK asso-
ciated with paxillin regardless of whether the GN4 cells were
treated with cytochalasin D or not. Although, cytochalasin D
pretreatment inhibited CADTK tyrosine phosphorylation and
prevented paxillin tyrosine phosphorylation in Ang II-treated
cells (Fig. 5), it did not disrupt the CADTK-paxillin association.
Paxillinzp125FAK complexes were not detected under these con-
ditions (with or without cytochalasin D) (Fig. 8B). The anti-
body, 2A7, used to immunoprecipitate p125FAK is the same
antibody that detects the p125FAK-paxillin association in
chicken embryo fibroblasts (37). Paxillin immunoblotting after
immunoprecipitating with p125FAK antibody, A17, also failed
to detect paxillinzp125FAK complexes in GN4 cells (data not
shown).3 X. Li and H. S. Earp, unpublished data.
FIG. 5. Cytochalasin D inhibits CADTK, p125FAK, and paxillin
tyrosine phosphorylation. GN4 cells were pretreated with 2 mM
cytochalasin D (CytoD) for 2 h and then treated with Ang II (1 mM) for
90 s or NaCl (0.7 M) for 5 min. Equal amounts of cell lysates were then
immunoprecipitated with anti-CADTK (A), anti-p125FAK (B), and anti-
paxillin (C) antibodies, respectively. Immunoprecipitates (IP) were then
analyzed by SDS-PAGE, followed by immunoblotting (IB) with anti-
Tyr(P) antibody (RC20H).
FIG. 6. Tyrosine-phosphorylated 68–75-kDa proteins complex
with CADTK but not with p125FAK. GN4 cells were treated with Ang
II (1 mM) for 90 s. Cells were then lysed and immunoprecipitated with
anti-CADTK or one of two anti-p125FAK (2A7, A17) antibodies. Immu-
noprecipitates were analyzed by SDS-PAGE, followed by immunoblot-
ting (IB) with the anti-Tyr(P) antibody (RC20H).
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To further examine the paxillin complexes, p125FAK and
CADTK were overexpressed by transient transfection cDNAs
driven by cytomegalovirus promotor in human 293(T) cells.
293(T) cells exhibit minimal p125FAK expression (as seen on an
overexposed immunoblot), but we could not detect any endog-
enous CADTK. As shown in Fig. 9, after transfection, p125FAK
tyrosine phosphorylation level was much higher than that
of CADTK (Fig. 9A). Immunoprecipitation demonstrated
p125FAKzpaxillin complex under this condition (Fig. 9C), ruling
out an experimental artifact as the reason for our failure to
detect p125FAKzpaxillin complex in GN4 cells.
To examine another potential CADTK substrate complex, we
tested CADTK immunoprecipitates from CADTK-transfected
293(T) cells for the presence of p130CAS. CADTK overexpres-
sion in human 293(T) cells allows detection of CADTK-p130CAS
association (Fig. 10) as defined by co-immunoprecipitation. In
contrast to paxillin, the CADTKzp130CAS complex was not de-
tected in GN4 cells (data not shown), but the experiment in Fig.
10 does demonstrate a direct interaction of this potential sub-
strate (p130CAS), kinase (CADTK) pair.
DISCUSSION
Ang II initiates its signal via Gq protein-coupled receptor-
activating phospholipase C, serine/threonine kinases, and at
least one tyrosine kinase that we have recently purified and
cloned and referred to as CADTK (16). Although CADTK is
stimulated by a calcium signal, the calcium effect is indirect as
neither calcium nor calcium/calmodulin directly activate the
enzyme. Treatment of GN4 cells with phorbol esters also acti-
vates CADTK, but the activation is slower than that of Ang II
or thapsigargin and is therefore also probably indirect. Thus,
the mechanism by which calcium and other signals regulate
CADTK is currently unknown. In GN4 cells, thapsigargin,
which produces a calcium signal and activates CADTK, also
stimulates both c-Jun N-terminal kinase and p70S6K but not
MAPK or p90RSK (16, 42, 43). However, in PC12 cells, agonist-
dependent CADTK/PYK2 stimulation increased Shc tyrosine
phosphorylation and MAPK activity. We are currently trying to
understand the basis of this cell type difference in CADTK
signaling and must, in addition, determine whether CADTK
and p125FAK have distinct effects on the MAPK pathway.
To broaden the comparison between CADTK and p125FAK,
we investigated the Ang II-dependent tyrosine phosphorylation
of paxillin, a protein tyrosine phosphorylated upon engagement
of cell surface integrins (37). In Swiss 3T3 cells (which do not
express CADTK), paxillin and p125FAK become coordinately
and substantially tyrosine-phosphorylated in response to a va-
riety of stimulators, including bombesin, lysophosphatidic acid,
platelet-derived growth factor, and GTPgS (38–41, 48). Paxil-
lin can also be phosphorylated in vitro by p60src and Csk, both
of which are potentially regulated and/or localized through
p125FAK (30). In this report, we show that Ang II rapidly
increased tyrosine phosphorylation of paxillin, tensin, and
p130CAS in adherent GN4 rat liver epithelial cells. The effect on
paxillin is the greatest. The increment in paxillin tyrosine
phosphorylation produced by CADTK agonists (i) is rapid (Fig.
1), (ii) correlates with CADTK activation for a range of agonists
(Figs. 2 and 5), (iii) correlates with the CADTK expression and
activation in GN4 and WB cells (Fig. 3), and (iv) is largely
calcium-dependent (Fig. 4). A key element of this argument is
depicted in Fig. 6. Tyrosine-phosphorylated p125FAK is ex-
pressed at levels that are similar or slightly greater than the
maximal level of tyrosine-phosphorylated CADTK. Since it is
known that the major autophosphorylation site in p125FAK is
Tyr397 (30, 49) and we have demonstrated the equivalent site
Tyr402 is the major autophosphorylation site in CADTK,3 the
comparison of maximal tyrosine phosphorylation of these two
enzymes provides a reasonable estimate of their relative ex-
pression. p125FAK is near maximally tyrosine-phosphorylated
FIG. 8. CADTK-paxillin association does not require the integ-
rity of the cytoskeleton. GN4 cells were pretreated with or without
cytochalasin D (2 mM) for 2 h, followed by Ang II (1 mM) stimulation for
the indicated times. Equal amounts of cell lysates were then immuno-
precipitated (IP) with anti-CADTK, anti-p125FAK, or anti-paxillin anti-
bodies, respectively. Immunoprecipitates were analyzed by SDS-PAGE,
followed by immunoblotting (IB) with anti-paxillin antibody.
FIG. 7. CADTK and paxillin form a non-covalent complex. GN4
cells were treated with Ang II (1 mM) or thapsigargin (2 mM) for 90 s.
Cells were then lysed in three different lysis buffers, low salt buffer (A),
high salt buffer (B), and RIPA buffer, containing 0.1% SDS (C), respec-
tively. Equal amounts of cell lysates were immunoprecipitated (IP) with
anti-CADTK antiserum. The supernatant of the first immunoprecipi-
tation was then immunoprecipitated with anti-paxillin antibody. Both
first and second immunoprecipitates were then analyzed by SDS-
PAGE, followed by immunoblot (IB) with anti-paxillin antibody.
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in confluent, untreated cells. Since p125FAK activity is thought
to be primarily controlled by extracellular factors, the near
maximal level of p125FAK activation may well dictate the basal
level of paxillin tyrosine phosphorylation. This is concordant
with the fact that basal level of paxillin Tyr(P) is equivalent in
WB and GN4 cell lines expressing similar amounts of p125FAK
(Fig. 3). Ang II treatment only minimally altered p125FAK
tyrosine phosphorylation (Fig. 6) and autokinase activity (15),
but Ang II increases CADTK tyrosine phosphorylation (Fig. 2)
and activity (16). This activation correlates with a substantial
increase in paxillin and smaller but definable increases in
tensin and p130CAS tyrosine phosphorylation.
The intracellular calcium chelator, BAPTA, significantly in-
hibits thapsigargin-dependent CADTK and paxillin tyrosine
phosphorylation. In agonist-treated cells, BAPTA inhibition
has less effect on p125FAK tyrosine phosphorylation than on
CADTK (Fig. 4), suggesting that CADTK is the tyrosine kinase
responsible for the Gq protein-coupled receptor-mediated in-
crease in paxillin tyrosine phosphorylation. However, we can-
not rule out other possibilities. First, CADTK tyrosine auto-
phosphorylation like that of p125FAK may provide SH2 domain
binding sites to recruit tyrosine kinases, such as Src family
tyrosine kinases (2, 28, 29, 49, 50). These enzymes in turn may
phosphorylate paxillin. We have shown a major autophospho-
rylation site (Tyr402 AEI) on CADTK is identical to Tyr397 AEI
in p125FAK (49, 50), and both are close to the consensus se-
quence (YEEI) recognized by the SH2 domain of p60src and its
family members (51). Our preliminary data show that CADTK
immune complexes can directly phosphorylate the N-terminal
portion of paxillin in vitro,4 but this does not preclude the
action of a CADTK-associated tyrosine kinase. Fig. 6 demon-
strates a high level of p125FAK Tyr(P) in resting cells, presum-
ably phosphorylated at Tyr397. The rapid, agonist-induced in-
creases in both CADTK and paxillin tyrosine phosphorylation
suggest direct CADTK phosphorylation of paxillin but again do
not rule out CADTK autophosphorylation followed by recruit-
ment of another tyrosine kinase. In this latter scenario, acti-
vated CADTK could recruit and activate a tyrosine kinase with
an affinity for CADTK Tyr402 greater than its affinity for
p125FAK Tyr397. Alternatively, other secondary mechanisms of
activation might occur via SH3-proline-rich region interac-
tions. It seems more likely that agonist-activated CADTK di-
rectly phosphorylates paxillin.
The CADTK and p125FAK similarity is higher within the
focal adhesion targeting domain that has two vinculin homol-
ogous domains (36). These two domains, which are essential for
paxillin binding, have been named paxillin binding sequence 1
and 2 (PBS1 and PBS2). Both PBS1 (919RSNDKVYENVT-
GLVKAVIEM938) and PBS2 (1029VDAKNLLDVIDQARL1043)
homologous domains are present in CADTK: (875RTDDLVYH-
NVMTLVEAVLEL894) and (986VDAKNLLDAVDQAKV999)
with 55 and 73% identity, respectively. Treatment with cy-
tochalasin D shows that CADTKzpaxillin complexes do not
require either tyrosine phosphorylation or an intact cytoskele-
ton (Figs. 7 and 8) suggesting that CADTK may directly asso-
ciate with paxillin through primary protein structures, e.g. the
two PBS1- and PBS2-like domains. In fact, we have demon-
strated that a glutathione S-transferase N terminus of paxillin
binds to CADTK synthesized by in vitro translation of the rat
CADTK cDNA using rabbit reticulocytes.3 Surprisingly,
p125FAK-paxillin association was not detected in GN4 cells
even though protein expression levels of p125FAK and CADTK
appear to be similar. Further experiments will be necessary to
determine the mechanism (direct or indirect) and domains
involved in CADTK and p125FAK interactions with cytoskeletal
proteins. This information could then be used to determine, in
epithelial cells, whether the affinity of CADTK for paxillin is
higher than that of p125FAK.
Since they are expressed in the same cells, p125FAK and
CADTK are not likely to be cell type-specific functional equiv-
alents. For example, CADTK cannot fully replace p125FAK as
p125FAK-deficient mice, produced by gene targeting, result in
mutant embryos (52). However, the two enzymes have similar-
ities; for example, cell adherence to extracellular matrix leads
to CADTK/RAFTK activation (53). The fact that CADTK and
p125FAK appear to have different abilities to complex with
paxillin suggests subtle differences in function, even with re-4 X. Li, M. D. Schaller, and H. S. Earp, unpublished results.
FIG. 9. CADTK-paxillin and p125FAK-paxillin associations are
present in CADTK and p125FAK-transfected human 293(T) cells.
Human 293(T) cells were transiently transfected with CADTK and
p125FAK expression constructs. Equal amounts of cell lysates were
immunoprecipitated (IP) with either anti-CADTK or anti-p125FAK an-
tibodies. Immunoprecipitates were then analyzed by SDS-PAGE, fol-
lowed by immunoblot (IB) with anti-Tyr(P) (A), anti-CADTK or anti-
p125FAK (B), and anti-paxillin (C) antibodies. This experiment is
representative of three separate transfections.
FIG. 10. CADTKzp130CAS complex is present in human 293(T)
cells transfected with CADTK. Human 293(T) cells were transiently
transfected with either 2.5 or 5 mg of pcDNA3-CADTK expression
constructs or with 5 mg of pcDNA3 vector. Equal amounts of cell lysates
were immunoprecipitated (IP) with either anti-p130CAS or anti-CADTK
(1–80) antibodies. Immunoprecipitates were then analyzed by SDS-
PAGE, followed by immunoblot (IB) with an anti-p130CAS antibody.
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spect to the cytoskeleton. Further experiments will help us
define the relationship between these two protein tyrosine
kinases.
Ang II treatment also increases p130CAS and tensin tyrosine
phosphorylation, and overexpression of CADTK in 293(T) cells
demonstrated CADTKzp130CAS complexes (Fig. 10). Transfect-
ing cells with Rous sarcoma virus or spreading of cells on
extracellular matrix induces both p130CAS and tensin tyrosine
phosphorylation (24, 54–57). Indeed, both p125FAK and Src can
phosphorylate these two cytoskeletal proteins in vitro (58, 59).
p130CAS can associate with p125FAK in vivo through its SH3
domain (32, 34). Interestingly, the proline-rich region of
p125FAK (711APPKPSR717), which interacts with the p130CAS
SH3 domain, is almost identical to (703PPPKPSR709) in
CADTK, and this may be the basis of CADTK-p130CAS associ-
ation detected in transfected 293(T) cells (Fig. 10). Whether
CADTK directly phosphorylates p130CAS and tensin remains to
be determined.
The role of tyrosine phosphorylation of paxillin, p130CAS, and
tensin in G protein-coupled receptor-directed signaling is cur-
rently unknown. Although no enzymatic activity has been de-
scribed, paxillin and tensin do form complexes with other cy-
toskeletal proteins such as vinculin and talin (47, 58). Tyrosine-
phosphorylated paxillin, p130CAS, and tensin may also provide
binding sites for the SH2 containing proteins such as Crk
family members (30, 34, 60, 61). In turn, Crk can associate with
a number of proteins through its SH3 domains, such as two
guanine nucleotide exchange proteins, C3G and SOS, and a
non-receptor tyrosine kinase, Abl (62–64). It will be interesting
to see whether CADTK induces paxillin, p130CAS, and tensin
tyrosine phosphorylation at sites different than those phospho-
rylated by p125FAK; if so, CADTK may bring in different SH2
containing proteins and initiate unique signaling pathways.
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